CoChat
Sign Up
Cited by 54Dementia and Cognitive Impairment ResearchPsychological Testing and AssessmentHistorical and Modern Theater Studies

Differentiating among stages of cognitive impairment in aging: Version 3 of the Uniform Data Set (UDS) neuropsychological test battery and MoCA index scores

Open access
Dodge, Hiroko H., Goldstein, Felicia C., Wakim, Nicole I, Gefen, Tamar, Teylan, Merilee, Chan, Kwun C.G., Kukull, Walter A., Barnes, Lisa L. +15 more·2020·Alzheimer's & Dementia: Translational Research & Clinical Interventions
DOI 10.1002/trc2.12103PMC PMC7683960
Open this paper in CoChat — free accountOpen PDF

Abstract

Introduction: Federally funded Alzheimer's Disease Centers in the United States have been using a standardized neuropsychological test battery as part of the National Alzheimer's Coordinating Center Uniform Data Set (UDS) since 2005. Version 3 (V3) of the UDS replaced the previous version (V2) in 2015. We compared V2 and V3 neuropsychological tests with respect to their ability to distinguish among the Clinical Dementia Rating (CDR) global scores of 0, 0.5, and 1. Methods: First, we matched participants receiving V2 tests (V2 cohort) and V3 tests (V3 cohort) in their cognitive functions using tests common to both versions. Then, we compared receiver‐operating characteristic (ROC) area under the curve in differentiating CDRs for the remaining tests. Results: Some V3 tests performed better than V2 tests in differentiating between CDR 0.5 and 0, but the improvement was limited to Caucasian participants. Discussion: Further efforts to improve the ability for early identification of cognitive decline among diverse racial groups are required.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/trc2.12103

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 32

  1. [1]Beekly DL, Ramos EM, Lee WW, et al. The National Alzheimer's Coordinating Center (NACC) database: the Uniform Data Set. Alzheimer Dis Assoc Disord. 2007; 21(3): 249‐ 258. 17804958
  2. [2]Weintraub S, Salmon D, Mercaldo N, et al. The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord. 2009; 23(2): 91‐ 101. 19474567 PMC2743984
  3. [3]Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord. 2006; 20(4): 210‐ 216. 17132964
  4. [4]Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993; 43(11): 2412‐ 2414. 8232972
  5. [6]McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3): 263‐ 269. 21514250 PMC3312024
  6. [7]Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3): 270‐ 279. 21514249 PMC3312027
  7. [8]Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3): 280‐ 292. 21514248 PMC3220946
  8. [9]Beekly DL, Ramos EM, van Belle G, et al. The National Alzheimer's Coordinating Center (NACC) Database: an Alzheimer disease database. Alzheimer Dis Assoc Disord. 2004; 18(4): 270‐ 277. 15592144
  9. [10]Weintraub S, Besser L, Dodge HH, et al. Version 3 of the Alzheimer Disease Centers' Neuropsychological Test Battery in the Uniform Data Set (UDS). Alzheimer Dis Assoc Disord. 2018; 32(1): 10‐ 17. 29240561 PMC5821520
  10. [11]Folstein MF, Folstein SE, McHugh PR. “Mini‐mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3): 189‐ 198. 1202204
  11. [12]Reitan RM. Validity of the Trail‐making Tests as an indication of organic brain damage. Percept Mot Skills. 1985; 8: 271‐ 276.
  12. [14]Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology. 1989; 39(9): 1159‐ 1165. 2771064
  13. [15]Mack WJ, Freed DM, Williams BW, Henderson VW. Boston Naming Test: shortened versions for use in Alzheimer's disease. J Gerontol. 1992; 47(3): P154‐ 158. 1573197
  14. [17]Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005; 53(4): 695‐ 699. 15817019
  15. [18]Goldstein FC, Milloy A, Loring DW, for the Alzheimer's Disease Neuroimaging I. Incremental validity of Montreal cognitive assessment index scores in mild cognitive impairment and Alzheimer disease. Dement Geriatr Cogn Disord. 2018; 45(1‐2): 49‐ 55. 29642074 PMC5971132
  16. [20]Ivanova I, Salmon DP, Gollan TH. The multilingual naming test in Alzheimer's disease: clues to the origin of naming impairments. J Int Neuropsychol Soc. 2013; 19(3): 272‐ 283. 23298442 PMC4356120
  17. [21]Possin KL, Laluz VR, Alcantar OZ, Miller BL, Kramer JH. Distinct neuroanatomical substrates and cognitive mechanisms of figure copy performance in Alzheimer's disease and behavioral variant frontotemporal dementia. Neuropsychologia. 2011; 49(1): 43‐ 48. 21029744 PMC3005024
  18. [22]Lezak MD, Howieson DB, Bigler ED, Tranel D. Neuropsychological Assessment. New York: Oxford University Press; 2012.
  19. [23]Monsell SE, Dodge HH, Zhou XH, et al. Results From the NACC uniform data set neuropsychological battery crosswalk study. Alzheimer Dis Assoc Disord. 2015; 30(2): 134‐ 139. PMC4834278 26485498
  20. [24]Carpenter J, Bithell J. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med. 2000; 19(9): 1141‐ 1164. 10797513
  21. [25]Julayanont P, Brousseau M, Chertkow H, Phillips N, Nasreddine ZS. Montreal Cognitive Assessment Memory Index Score (MoCA‐MIS) as a predictor of conversion from mild cognitive impairment to Alzheimer's disease. J Am Geriatr Soc. 2014; 62(4): 679‐ 684. 24635004
  22. [26]Breitner JCS. How can we really improve screening methods for AD prevention trials? Alzheimers Dement (N Y). 2016; 2(1): 45‐ 47. 29067292 PMC5644270
  23. [27]Borson S, Sehgal M, Chodosh J. Monetizing the MoCA: what now? J Am Geriatr Soc. 2019; 67(11): 2229‐ 2231. 31478562
  24. [28]Lin M, Gong P, Yang T, Ye J, Albin RL, Dodge HH. Big data analytical approaches to the NACC dataset: aiding preclinical trial enrichment. Alzheimer Dis Assoc Disord. 2018; 32(1): 18‐ 27. 29227306 PMC5854492
  25. [29]Milani SA, Marsiske M, Cottler LB, Chen X, Striley CW. Optimal cutoffs for the Montreal Cognitive Assessment vary by race and ethnicity. Alzheimers Dement (Amst). 2018; 10: 773‐ 781. 30505927 PMC6247398
  26. [30]Goldstein FC, Ashley AV, Miller E, Alexeeva O, Zanders L, King V. Validity of the montreal cognitive assessment as a screen for mild cognitive impairment and dementia in African Americans. J Geriatr Psychiatry Neurol. 2014; 27(3): 199‐ 203. 24614202
  27. [31]Sink KM, Craft S, Smith SC, et al. Montreal Cognitive Assessment and Modified Mini Mental State Examination in African Americans. J Aging Res. 2015; 2015: 872018. 26618003 PMC4649096
  28. [32]Rossetti HC, Lacritz LH, Cullum CM, Weiner MF. Normative data for the Montreal Cognitive Assessment (MoCA) in a population‐based sample. Neurology. 2011; 77(13): 1272‐ 1275. 21917776
  29. [33]Rossetti HC, Smith EE, Hynan LS, et al. Detection of Mild cognitive impairment among community‐dwelling African Americans using the montreal cognitive assessment. Arch Clin Neuropsychol. 2019; 34(6): 809‐ 813. 30517598 PMC6930383
  30. [34]Rossetti HC, Lacritz LH, Hynan LS, Cullum CM, Van Wright A, Weiner MF. Montreal cognitive assessment performance among community‐dwelling African Americans. Arch Clin Neuropsychol. 2017; 32(2): 238‐ 244. 28365749 PMC5860177
  31. [35]Sachs BC, Steenland K, Zhao L, et al. Expanded Demographic Norms for Version 3 of the Alzheimer Disease Centers' Neuropsychological Test Battery in the Uniform Data Set. Alzheimer Dis Assoc Disord. 2020; 34(3): 191‐ 197. 32483017 PMC7842186
  32. [36]Ho DE, Imai K, King G, Stuart EA. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw. 2011; 42(8): 1‐ 28.

Cited by

Sorted by citations

Authors
Dodge, H. H., Goldstein, F. C., Wakim, N. I., Gefen, T., Teylan, M., Chan, K. C. G., Kukull, W. A., Barnes, L. L., Giordani, B., Hughes, T. M., Kramer, J. H., Loewenstein, D. A., Marson, D. C., Mungas, D. M., Mattek, N., Sachs, B. C., Salmon, D. P., Willis‐Parker, M., Welsh‐Bohmer, K. A., Wild, K. V., Morris, J. C., Weintraub, S., & National Alzheimer's Coordinating Center (NACC)
Affiliations
  • Oregon Health & Science University (US)
  • Emory University (US)
  • University of Michigan (US)
  • Northwestern University (US)
  • University of Washington (US)
  • Rush University Medical Center (US)
  • Wake Forest University Health Sciences (US)
  • University of California, San Francisco (US)
  • University of Miami (US)
  • University of Alabama at Birmingham (US)
  • University of California, Davis (US)
  • University of California San Diego (US)
  • Alzheimer's Disease Research Center Duke University Durham North Carolina USA
  • Washington University in St. Louis (US)
  • The Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Department of Psychiatry and Behavioral Sciences, Feinberg School of Medicine, Northwestern University Chicago Illinois USA
Corresponding author
Dodge, Hiroko H.
ORCID
Venue
Alzheimer's & Dementia: Translational Research & Clinical Interventions
Publisher
Wiley
Published
2020-01
Volume
6
Issue
1
Pages
e12103-e12103
ISSN
2352-8737 (ISSN-L)
DOI
10.1002/trc2.12103
PMC
PMC7683960
OpenAlex
W3108183223
Cited by
54
References
3
Citations by year
2026: 8 · 2025: 15 · 2024: 11 · 2023: 11 · 2022: 4 · 2021: 5
FWCI
3.63
Type
journal article
Language
en
Update notices
erratum (2021-02-14)
Open access
Licence
Locations
  • Alzheimer s & Dementia Translational Research & Clinical Interventions (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institutes of Health (AG016976, AG019610, AG013846)
  • National Institute on Aging (AG 016976, P30AG053760, P30AG010129, P30AG010133, P30AG049638, P30AG028383, P30AG012300, P50AG005133, U01AG016976, P50AG005131, P50AG005138, AG019610, P30AG010124, P50AG016573, P50AG047366, P30AG008017, P30AG010161, P30AG008051, P50AG008702, P50AG033514, P30AG035982, AG013846, P50AG005681, P50AG005142, P50AG047270, P30AG019610, P50AG005146, R01AG062566, P30AG013846, P50AG005136, P50AG005134, P30AG013854, P50AG025688, P50AG047266, P30AG062429, P30AG066518, P30AG072976, U24AG072122, P30AG066511, P50AG023501, P50AG016574)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Social Sciences › Psychology › Applied Psychology › Psychological Testing and Assessment
  • Social Sciences › Psychology › Clinical Psychology › Historical and Modern Theater Studies
Keywords
neuropsychological test battery, Montreal Cognitive Assessment, Clinical Dementia Rating, age-related cognitive decline, Alzheimer's disease, test version comparison, early detection of cognitive decline, racial differences, older adults

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review